Spinal cord sarcoma

Summary

Spinal cord sarcoma (MONDO:0001894) is a cancer. A subtype of central nervous system sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord sarcoma
Mondo ID	MONDO:0001894
DOID	DOID:14152
NCIT	C5152
UMLS	C1336049
MedGen	233459
GARD	0023032
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	yes

Also known as: sarcoma of spinal cord · sarcoma of the spinal cord · spinal cord sarcoma

Disease family

This is a subtype of central nervous system sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system sarcoma › spinal cord sarcoma

Related subtypes (11): brain sarcoma, central nervous system rhabdomyosarcoma, central nervous system angiosarcoma, central nervous system leiomyosarcoma, central nervous system fibrosarcoma, meningeal sarcoma, intracranial extraskeletal myxoid chondrosarcoma, central nervous system extraskeletal osteosarcoma, malignant peripheral nerve sheath tumor, atypical teratoid rhabdoid tumor, isolated melanotic schwannoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.